首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure
【24h】

Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure

机译:Peroxiredoxins和tropomyosins作为肺癌和石棉暴露的血浆生物标志物

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The prognosis of lung cancer is poor due to late diagnosis, the lack of established screening programs, and the paucity of early biomarkers for high-risk populations. Plasma proteome analysis was used to identify novel biomarkers for diagnosing lung cancer, and to unravel the mechanisms of underlying pathogenesis. Plasma proteins obtained from asbestos-exposed lung cancer cases detected by CT screening, asbestos-exposed subjects, clinical lung cancer patients, and healthy tobacco smokers, 5-6 cases in each group, were separated by two-dimensional gel electrophoresis, and identified with tandem mass spectrometry (LC-MS/MS). Nine proteins were selected for immunological confirmation in a test or validation set of plasma samples from an additional 49 clinical lung cancer cases, 66 asbestos-exposed patients, and 107 healthy tobacco smokers. Twenty-eight unique proteins were differentially expressed between the four study groups (p<0.05). Peroxiredoxin 1 (PRX1) was detected as a novel plasma marker for lung cancer (p=0.001). We also confirmed the previously found association of serum amyloid A with lung cancer (p<0.001). High plasma levels of tropomyosin 4 (TPM4: p<0.001) and peroxiredoxins 1 and 2 (PRX2: p<0.001) correlated with asbestos exposure or a diagnosis of asbestosis. PRX1 and PRX2 exhibited an inverse correlation with tobacco smoking (p<0.001). Plasma peroxiredoxins 1 and 2, and tropomyosin 4 were shown to associate with asbestos-exposure, and peroxiredoxin 1 with lung cancer. High plasma levels of peroxiredoxin 1 may result from genetic damage caused by reactive oxygen species. This study has identified several biomarkers worthy of further investigation in lung cancer and asbestos-related diseases.
机译:由于晚期诊断,缺乏既定的筛查程序以及高危人群缺乏早期生物标志物,肺癌的预后很差。血浆蛋白质组学分析用于鉴定诊断肺癌的新型生物标志物,并阐明潜在的发病机理。通过CT筛查从接触石棉的肺癌病例,接触石棉的受试者,临床肺癌患者和健康的吸烟者中获得的血浆蛋白(每组5-6例)通过二维凝胶电泳进行分离,并通过串联质谱(LC-MS / MS)。从另外49例临床肺癌病例,66名接触石棉的患者和107名健康吸烟者的血浆样品的测试或验证集中选择了9种蛋白质进行免疫学确认。四个研究组之间有28种独特的蛋白质差异表达(p <0.05)。 Peroxiredoxin 1(PRX1)被检测为肺癌的新型血浆标志物(p = 0.001)。我们还证实了先前发现的血清淀粉样蛋白A与肺癌的相关性(p <0.001)。血浆高水平的原肌球蛋白4(TPM4:p <0.001)和过氧化物酶1和2(PRX2:p <0.001)与石棉暴露或石棉沉着症的诊断有关。 PRX1和PRX2与吸烟呈负相关(p <0.001)。血浆过氧化物酶1和2,以及原肌球蛋白4与石棉接触有关,过氧化物酶1与肺癌有关。血浆高水平的过氧化物酶1可能是由于活性氧引起的遗传损伤。这项研究确定了一些值得进一步研究的肺癌和石棉相关疾病的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号